Johannes Francois Fahrmann

This study identifies KRAS-driven metabolic reprogramming through MFSD2A-mediated lysophosphatidylcholine scavenging as a driver of PDAC progression and shows that targeting this pathway with edelfosine has anti-cancer effects.

This study links low stool valerate to CAR T-cell dysfunction in B-cell lymphoma and shows valerate supplementation improves CAR T function.

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

This study identifies aberrant CD14 expression in breast tumor cells as a marker of poor clinical outcomes and aggressive disease.

This study evaluates combinations of PDAC biomarkers across multiple labs, finding improved sensitivity and specificity for early-stage detection compared to CA19-9 alone.

The paper introduces SMAGS, a regression framework that maximizes sensitivity at a given specificity for binary classification, showing 14% improvement in sensitivity on a colorectal cancer dataset.

This study shows that P2-HNF4 regulates ketogenesis in the liver and is involved in circadian metabolism, with implications for gender-specific ketone body levels.